Polar Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Polar Capital’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-18,750	Closed	-$711K	–	265
2016 Q3	$711K	Buy	18,750 +1,824	+11%	+$57.4K	0.01%	241
2016 Q2	$504K	Buy	+16,926	New	+$595K	0.01%	251
2015 Q4	–	Sell	-12,478	Closed	-$469K	–	282
2015 Q3	$469K	Sell	12,478 -5,022	-29%	-$231K	0.01%	261
2015 Q2	$343K	Buy	+17,500	New	+$387K	0.01%	275

Other funds holding RCKT

RCP

Rho Capital Partners New York $20.4M AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Polar Capital's RCKT Position: Q4 2016 in Review

Polar Capital sold out of Rocket Pharmaceuticals (RCKT) in Q4 2016, closing a stake of 18,750 shares — an estimated $711K sold.

Polar Capital first reported a position in RCKT in Q2 2015 and held it in 4 quarters. The position peaked at $711K in Q3 2016. 82 funds tracked by Wall St. Rank hold RCKT as of Q4 2016.

Polar Capital reported no remaining Rocket Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Polar Capital sold 18,750 Rocket Pharmaceuticals shares in Q4 2016, an estimated $711K.
Polar Capital first reported a position in Rocket Pharmaceuticals in Q2 2015 and held it in 4 quarters.
Polar Capital's Rocket Pharmaceuticals position peaked at $711K in Q3 2016.
82 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2016.

Based on Polar Capital's 13F filing for Q4 2016, filed 14 Feb 2017.